Biologic Drugs

Aug 28, 2018
By Pharmaceutical Technology Editors
Preliminary survey results rank the United States, Germany, and Japan as tier-one nations for bioprocessing performance and potential.
Aug 28, 2018
By Pharmaceutical Technology Editors
The European Commission (EC) has approved Novartis’ chimeric antigen receptor T cell (CAR-T) cell therapy Kymriah for the treatment of B-cell acute lymphoblastic leukemia and relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
Aug 17, 2018
By Pharmaceutical Technology Editors
The company’s purpose-built facility in Norwich, United Kingdom specializes in plant-based expression of proteins, metabolites, and complex natural products.
Aug 14, 2018
By Pharmaceutical Technology Editors
Drug product approval from FDA follows previous approvals from European and Japanese authorities.
Aug 13, 2018
By Pharmaceutical Technology Editors
The new drug, Onpattro (patisiran), by Alnylam Pharmaceuticals, is in a new class of drugs called small interfering ribonucleic acid (siRNA) treatment.
Aug 06, 2018
By Pharmaceutical Technology Editors
The companies will collaborate on the discovery, development, and commercialization of cell therapies for cancer.
Aug 02, 2018
Pharmaceutical Technology
Development costs and time to market continue to put pressure on the biopharma industry, driving the need for innovation in methods and technologies.
Aug 02, 2018
Pharmaceutical Technology
Frustrated by slow market adoption, Gottlieb maps out new plan for biosimilar competition.
Aug 02, 2018
Pharmaceutical Technology
Materials in contact with a drug must be fully characterized to ensure they do not negatively affect the safety and efficacy of the product.
Aug 01, 2018
Pharmaceutical Technology
CMOs have been active over the past year in expanding their biologics production and capabilities.
native1_300x100
lorem ipsum